INFLUENZA G1 mHA + aluminum hydroxide

This drug is a **combination vaccine candidate** consisting of a recombinant, stabilized trimeric influenza A group 1 hemagglutinin (HA) stem protein antigen (known as INFLUENZA G1 mHA, also called H1 stem v2) formulated with **aluminum hydroxide** as an adjuvant. The antigen is designed to elicit **broadly neutralizing antibodies** against influenza A group 1 viruses, with the aim of achieving broader and more durable protection compared to conventional seasonal influenza vaccines. Aluminum hydroxide enhances immune responses by acting as an adjuvant—primarily by promoting antigen uptake and activating innate immune pathways that stimulate antibody production. In preclinical studies, this combination induced strong and broad HA-specific antibody responses and demonstrated persistent antibody presence over several months in non-human primates. It is being evaluated as a potential universal influenza vaccine candidate, focusing on increasing breadth and durability of humoral responses against diverse influenza strains[1].

Other names

recombinant H1 stem antigen + aluminum hydroxide